Compare Regeneron Pharmaceuticals Inc (REGN) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while State Street Technology Select Sector SPDR ETF trades at $198.78 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| REGN | XLK | |
|---|---|---|
Market Cap | $76.14B | $132.55B |
Volume | 500,239 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $852.03 | $202.00 |
52-Week Low | $557.73 | $127.49 |
Typical Hold Time | 107 Days | 50 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
XLK trades at $197.79, down 1.79% on the day, with a bullish technical signal driven by moving averages. The ETF shows neutral oscillators and key support at $196. Recent news highlights concentration risks in its holdings, with some analysts favoring alternative tech ETFs for better diversification. Dividend activity is scheduled for late 2026.
Outlook remains cautiously optimistic given bullish technicals, but concentration in chip stocks poses a risk. Opportunities include AI-driven growth exposure, while risks involve interest rate sensitivity and sector-specific volatility. Investors should weigh diversification against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
